» Articles » PMID: 29940269

Endoplasmic Reticulum Stress Signalling and the Pathogenesis of Non-alcoholic Fatty Liver Disease

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2018 Jun 26
PMID 29940269
Citations 331
Authors
Affiliations
Soon will be listed here.
Abstract

The global epidemic of obesity has been accompanied by a rising burden of non-alcoholic fatty liver disease (NAFLD), with manifestations ranging from simple steatosis to non-alcoholic steatohepatitis, potentially developing into hepatocellular carcinoma. Although much attention has focused on NAFLD, its pathogenesis remains largely obscure. The hallmark of NAFLD is the hepatic accumulation of lipids, which subsequently leads to cellular stress and hepatic injury, eventually resulting in chronic liver disease. Abnormal lipid accumulation often coincides with insulin resistance in steatotic livers and is associated with perturbed endoplasmic reticulum (ER) proteostasis in hepatocytes. In response to chronic ER stress, an adaptive signalling pathway known as the unfolded protein response is triggered to restore ER proteostasis. However, the unfolded protein response can cause inflammation, inflammasome activation and, in the case of non-resolvable ER stress, the death of hepatocytes. Experimental data suggest that the unfolded protein response influences hepatic tumour development, aggressiveness and response to treatment, offering novel therapeutic avenues. Herein, we provide an overview of the evidence linking ER stress to NAFLD and discuss possible points of intervention.

Citing Articles

Induction of MASH-like pathogenesis in the Nwd1 mouse liver.

Yamada S, Ogawa H, Funato M, Kato M, Nakadate K, Mizukoshi T Commun Biol. 2025; 8(1):348.

PMID: 40069352 PMC: 11897295. DOI: 10.1038/s42003-025-07717-5.


Aflatoxin B1-Induced Apoptosis in Donkey Kidney via EndoG-Mediated Endoplasmic Reticulum Stress.

Ji Y, Zhang Y, Si W, Guo J, Liu G, Wang C Vet Sci. 2025; 12(2).

PMID: 40005890 PMC: 11860441. DOI: 10.3390/vetsci12020130.


Protective role of sulforaphane in lipid metabolism-related diseases.

Zhao L, Li J, Dang Y, Fisher D, Hien N, Musabaev E Mol Biol Rep. 2025; 52(1):241.

PMID: 39961997 DOI: 10.1007/s11033-025-10358-w.


Glucokinase activator improves glucose tolerance and induces hepatic lipid accumulation in mice with diet-induced obesity.

Cai N, Chen X, Liu J, Wen Z, Wen S, Zeng W Liver Res. 2025; 7(2):124-135.

PMID: 39958949 PMC: 11791924. DOI: 10.1016/j.livres.2023.05.003.


Activin E is a new guardian protecting against hepatic steatosis via inhibiting lipolysis in white adipose tissue.

Park S, Cho Y, Son S, Hur J, Kim Y, Oh H Exp Mol Med. 2025; 57(2):466-477.

PMID: 39948368 PMC: 11873131. DOI: 10.1038/s12276-025-01403-6.